Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment

K. Hemminki, J. Hemminki, A. Försti, A. Sud

. 2023 ; 37 (4) : 854-863. [pub] 20230224

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010548

Grantová podpora
Department of Health - United Kingdom

Studies of survival in hematological malignancies (HMs) have generally shown an improvement over time, although most of these studies are limited by a short follow-up period. Using the NORDCAN database with data from Denmark, Finland, Norway and Sweden, we follow periodic increases in relative survival in seven HMs through half a century up to 2015-2019. Five-year survival improved in all seven HMs, reaching 90% for Hodgkin lymphoma (HL), myeloproliferative neoplasias and chronic lymphocytic leukemia (CLL), 60% for multiple myeloma (MM) and chronic myeloid leukemias (CMLs), 50% for the myelodysplastic syndromes and 30% for acute myeloid leukemia (AML). Improvements in survival over 50 years ranged from 20% to more than 50% units across the different HMs. The likely reasons for such progress include earlier diagnoses, improved risk stratification and advances in treatment. We observed differing temporal trends in improvements in survival. The gradual increases observed in HL, CLL and AML highlight the impact of optimization of existing therapies and improvements in diagnostics and risk stratification, whereas the rapid increases observed in the CMLs and MM highlight the impact of novel therapies. Recent therapeutic advances may further improve survival in HMs where survival remains low such as in AML.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010548
003      
CZ-PrNML
005      
20230801132506.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-023-01852-w $2 doi
035    __
$a (PubMed)36828868
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Hemminki, Kari $u Biomedical Center, Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, 30605, Pilsen, Czech Republic. K.Hemminki@dkfz.de $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany. K.Hemminki@dkfz.de $1 https://orcid.org/0000000227693316 $7 mzk20201092711
245    10
$a Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment / $c K. Hemminki, J. Hemminki, A. Försti, A. Sud
520    9_
$a Studies of survival in hematological malignancies (HMs) have generally shown an improvement over time, although most of these studies are limited by a short follow-up period. Using the NORDCAN database with data from Denmark, Finland, Norway and Sweden, we follow periodic increases in relative survival in seven HMs through half a century up to 2015-2019. Five-year survival improved in all seven HMs, reaching 90% for Hodgkin lymphoma (HL), myeloproliferative neoplasias and chronic lymphocytic leukemia (CLL), 60% for multiple myeloma (MM) and chronic myeloid leukemias (CMLs), 50% for the myelodysplastic syndromes and 30% for acute myeloid leukemia (AML). Improvements in survival over 50 years ranged from 20% to more than 50% units across the different HMs. The likely reasons for such progress include earlier diagnoses, improved risk stratification and advances in treatment. We observed differing temporal trends in improvements in survival. The gradual increases observed in HL, CLL and AML highlight the impact of optimization of existing therapies and improvements in diagnostics and risk stratification, whereas the rapid increases observed in the CMLs and MM highlight the impact of novel therapies. Recent therapeutic advances may further improve survival in HMs where survival remains low such as in AML.
650    _2
$a lidé $7 D006801
650    12
$a chronická lymfatická leukemie $7 D015451
650    12
$a hematologické nádory $x epidemiologie $x terapie $7 D019337
650    12
$a Hodgkinova nemoc $7 D006689
650    12
$a mnohočetný myelom $x epidemiologie $x terapie $7 D009101
650    12
$a akutní myeloidní leukemie $x terapie $7 D015470
651    _2
$a Skandinávie a severské státy $x epidemiologie $7 D012537
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hemminki, Janne $u Biomedical Center, Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, 30605, Pilsen, Czech Republic
700    1_
$a Försti, Asta $u Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
700    1_
$a Sud, Amit $u Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK $u Haemato-oncology Unit, The Royal Marsden Hospital NHS Foundation Trust, Sutton, UK $1 https://orcid.org/0000000261330164
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 37, č. 4 (2023), s. 854-863
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36828868 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132503 $b ABA008
999    __
$a ok $b bmc $g 1963148 $s 1196813
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 37 $c 4 $d 854-863 $e 20230224 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
GRA    __
$p Department of Health $2 United Kingdom
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace